The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Myeloid-derived suppressor cell quantity prior to treatment with ipilimumab at 10mg/kg to predict for overall survival in patients with metastatic melanoma.
Shigehisa Kitano
No relevant relationships to disclose
Michael Andrew Postow
No relevant relationships to disclose
Czrina Cortez
No relevant relationships to disclose
Teresa Rasalan
No relevant relationships to disclose
Humilidad F. Gallardo
No relevant relationships to disclose
Katherine Panageas
No relevant relationships to disclose
Jianda Yuan
No relevant relationships to disclose
Jedd D. Wolchok
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Alexander M. Lesokhin
No relevant relationships to disclose